IGM Biosciences Revises its Collaboration with Sanofi

Share this
IGM Bioscience

IGM Biosciences Revises its Collaboration with Sanofi


  • IGM Biosciences and Sanofi have revised the previous exclusive worldwide agreement to solely develop 3 immunology/inflammation targets. IGM will keep the worldwide rights to its technology related to the oncology targets nominated by Sanofi
  • Under the agreement, IGM will be responsible for the research & development of the targets covering the cost of P-I study for up to two constructs per target. Sanofi will handle further development & commercialization activities & related costs
  • IGM is entitled to receive a total of ~$1,065M as development, regulatory & commercial milestones per target plus tiered high single-digit to low-teen sales-based royalties

Ref: IGM Biosciences | Image: IGM Biosciences

Related News:- IGM Biosciences Entered into a Clinical Collaboration Agreement with ADC to Evaluate Imvotamab (IGM-2323) + Zynlonta (loncastuximab tesirine-lpyl) for B Cell Non-Hodgkin’s Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions